|
03 Feb 2011 |
RXi Pharmaceuticals Initiates Development Program for Dermal Anti-Scarring Product Candidate
|
|
03 Feb 2011 |
Marina Biotech and The Debiopharm Group Partner to Develop and Commercialize RNAi-Based Therapies for the Treatment of Bladder Cancer
|
|
02 Feb 2011 |
Isis Initiates Phase 1 Clinical Trial of ISIS-FXIRx to Treat Clotting Disorders
|
|
28 Jan 2011 |
Arteriocyte Receives FDA Approval to Move Forward with Critical Limb Ischemia Trial
|
|
27 Jan 2011 |
RXi Pharmaceuticals Announces Positive Initial Results in microRNA Therapeutics
|
|
27 Jan 2011 |
The University of Massachusetts and Lundbeck Enter Research Collaboration to Explore Potential Targeted Therapy for Huntington’s Disease
|
|
25 Jan 2011 |
Alnylam Receives Positive Opinion for Orphan Drug Designation from European Medicines Agency for ALN-TTR01, an RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis
|
|
20 Jan 2011 |
Overview of Aastrom RESTORE-CLI and IMPACT-DCM Clinical Results Presented Today at the Conference on Cell Therapy for Cardiovascular Disease
|
|
19 Jan 2011 |
Geron Initiates Phase 2 Clinical Trial of Imetelstat in Essential Thrombocythemia
|
